{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:04:32Z","timestamp":1790049872861,"version":"4.0.1"},"reference-count":62,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R35GM162430"],"award-info":[{"award-number":["R35GM162430"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["molpharm.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Pharmacology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.molpha.2026.100155","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:41:30Z","timestamp":1789195290000},"page":"100155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A conserved conformation-dependent mechanism for the TREK two-pore domain potassium channel inhibitors carvedilol and fluphenazine"],"prefix":"10.1016","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-3618-4424","authenticated-orcid":false,"given":"Joelle","family":"Reich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8593-2605","authenticated-orcid":false,"given":"Paul M.","family":"Riegelhaupt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Tucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0859-3854","authenticated-orcid":false,"given":"Conor","family":"McClenaghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.molpha.2026.100155_bib1","doi-asserted-by":"crossref","first-page":"402","DOI":"10.4161\/chan.5.5.16469","article-title":"Molecular regulations governing TREK and TRAAK channel functions","volume":"5","author":"Noel","year":"2011","journal-title":"Channels (Austin)"},{"issue":"4","key":"10.1016\/j.molpha.2026.100155_bib2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nrn2117","article-title":"The neuronal background K2P channels: focus on TREK1","volume":"8","author":"Honore","year":"2007","journal-title":"Nat Rev Neurosci"},{"issue":"11","key":"10.1016\/j.molpha.2026.100155_bib3","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1038\/sj.emboj.7601116","article-title":"TREK-1, a K+ channel involved in polymodal pain perception","volume":"25","author":"Alloui","year":"2006","journal-title":"EMBO J"},{"issue":"1","key":"10.1016\/j.molpha.2026.100155_bib4","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1038\/ncomms3941","article-title":"Activation of TREK-1 by morphine results in analgesia without adverse side effects","volume":"4","author":"Devilliers","year":"2013","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.molpha.2026.100155_bib5","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1038\/emboj.2009.57","article-title":"The mechano-activated K+ channels TRAAK and TREK-1 control both warm and cold perception","volume":"28","author":"No\u00ebl","year":"2009","journal-title":"EMBO J"},{"issue":"12","key":"10.1016\/j.molpha.2026.100155_bib6","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1016\/j.pain.2014.09.013","article-title":"Role of the TREK2 potassium channel in cold and warm thermosensation and in pain perception","volume":"155","author":"Pereira","year":"2014","journal-title":"Pain"},{"issue":"7663","key":"10.1016\/j.molpha.2026.100155_bib7","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/nature22988","article-title":"K2P2.1 (TREK-1)-activator complexes reveal a cryptic selectivity filter binding site","volume":"547","author":"Lolicato","year":"2017","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.molpha.2026.100155_bib8","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.bmcl.2019.04.048","article-title":"Towards a TREK-1\/2 (TWIK-related K+ channel 1 and 2) dual activator tool compound: multi-dimensional optimization of BL-1249","volume":"29","author":"Iwaki","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"issue":"5","key":"10.1016\/j.molpha.2026.100155_bib9","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1021\/acschemneuro.5c00032","article-title":"Discovery of ONO-2920632 (VU6011887): a highly selective and CNS penetrant TREK-2 (TWIK-related K+ channel 2) preferring activator in vivo tool compound","volume":"16","author":"Yashiro","year":"2025","journal-title":"ACS Chem Neurosci"},{"issue":"1","key":"10.1016\/j.molpha.2026.100155_bib10","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1146\/annurev-pharmtox-030920-111536","article-title":"Two-pore domain potassium channels as drug targets: anesthesia and beyond","volume":"61","author":"Mathie","year":"2021","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"3","key":"10.1016\/j.molpha.2026.100155_bib11","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/bph.12953","article-title":"Targeting two-pore domain K(+) channels TREK-1 and TASK-3 for the treatment of depression: a new therapeutic concept","volume":"172","author":"Borsotto","year":"2015","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.molpha.2026.100155_bib12","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.pharmthera.2018.10.003","article-title":"Fighting against depression with TREK-1 blockers: past and future. A focus on spadin","volume":"194","author":"Djillani","year":"2019","journal-title":"Pharmacol Ther"},{"issue":"15","key":"10.1016\/j.molpha.2026.100155_bib13","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1073\/pnas.1522748113","article-title":"Mixing and matching TREK\/TRAAK subunits generate heterodimeric K2P channels with unique properties","volume":"113","author":"Blin","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"issue":"15","key":"10.1016\/j.molpha.2026.100155_bib14","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1073\/pnas.1522459113","article-title":"Heterodimerization within the TREK channel subfamily produces a diverse family of highly regulated potassium channels","volume":"113","author":"Levitz","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"issue":"26","key":"10.1016\/j.molpha.2026.100155_bib15","doi-asserted-by":"crossref","first-page":"13649","DOI":"10.1074\/jbc.M116.719039","article-title":"Formation of functional heterodimers by TREK-1 and TREK-2 two-pore domain potassium channel subunits","volume":"291","author":"Czirjak","year":"2016","journal-title":"J Biol Chem"},{"issue":"7529","key":"10.1016\/j.molpha.2026.100155_bib16","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/nature14013","article-title":"Physical mechanism for gating and mechanosensitivity of the human TRAAK K+ channel","volume":"516","author":"Brohawn","year":"2014","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.molpha.2026.100155_bib17","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1073\/pnas.1218950110","article-title":"Domain-swapped chain connectivity and gated membrane access in a Fab-mediated crystal of the human TRAAK K+ channel","volume":"110","author":"Brohawn","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6067","key":"10.1016\/j.molpha.2026.100155_bib18","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1126\/science.1213808","article-title":"Crystal structure of the human K2P TRAAK, a lipid\u2013 and mechano-sensitive K+ ion channel","volume":"335","author":"Brohawn","year":"2012","journal-title":"Science"},{"issue":"6227","key":"10.1016\/j.molpha.2026.100155_bib19","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1126\/science.1261512","article-title":"K2P channel gating mechanisms revealed by structures of TREK-2 and a complex with Prozac","volume":"347","author":"Dong","year":"2015","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.molpha.2026.100155_bib20","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.neuron.2014.11.017","article-title":"Transmembrane helix straightening and buckling underlies activation of mechanosensitive and thermosensitive K2P channels","volume":"84","author":"Lolicato","year":"2014","journal-title":"Neuron"},{"issue":"17","key":"10.1016\/j.molpha.2026.100155_bib21","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1038\/emboj.2011.268","article-title":"The pore structure and gating mechanism of K2P channels","volume":"30","author":"Piechotta","year":"2011","journal-title":"EMBO J"},{"issue":"5","key":"10.1016\/j.molpha.2026.100155_bib22","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.cell.2016.02.002","article-title":"A non-canonical voltage-sensing mechanism controls gating in K2P K(+) channels","volume":"164","author":"Schewe","year":"2016","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.molpha.2026.100155_bib23","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1085\/jgp.201611601","article-title":"Polymodal activation of the TREK-2 K2P channel produces structurally distinct open states","volume":"147","author":"McClenaghan","year":"2016","journal-title":"J Gen Physiol"},{"issue":"5","key":"10.1016\/j.molpha.2026.100155_bib24","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.str.2017.03.006","article-title":"Bilayer-mediated structural transitions control mechanosensitivity of the TREK-2 K2P channel","volume":"25","author":"Aryal","year":"2017","journal-title":"Structure"},{"issue":"6","key":"10.1016\/j.molpha.2026.100155_bib25","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.bpj.2018.01.030","article-title":"Mechanism of mechanosensitive gating of the TREK-2 potassium channel","volume":"114","author":"Brennecke","year":"2018","journal-title":"Biophys J"},{"issue":"40","key":"10.1016\/j.molpha.2026.100155_bib26","doi-asserted-by":"crossref","first-page":"E8343","DOI":"10.1073\/pnas.1708990114","article-title":"Asymmetric mechanosensitivity in a eukaryotic ion channel","volume":"114","author":"Clausen","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"10.1016\/j.molpha.2026.100155_bib27","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s00424-025-03089-1","article-title":"Thermosensitivity of TREK K2P channels is controlled by a PKA switch and depends on the microtubular network","volume":"477","author":"Cordeiro","year":"2025","journal-title":"Pflugers Arch"},{"issue":"17","key":"10.1016\/j.molpha.2026.100155_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2021.166995","article-title":"Structural insights into the mechanisms and pharmacology of K(2P) potassium channels","volume":"433","author":"Natale","year":"2021","journal-title":"J Mol Biol"},{"issue":"S3","key":"10.1016\/j.molpha.2026.100155_bib29","doi-asserted-by":"crossref","first-page":"87","DOI":"10.33594\/000000339","article-title":"Molecular pharmacology of K(2P) potassium channels","volume":"55","author":"Decher","year":"2021","journal-title":"Cell Physiol Biochem"},{"issue":"13","key":"10.1016\/j.molpha.2026.100155_bib30","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1038\/sj.emboj.7600234","article-title":"TREK-1, a K+ channel involved in neuroprotection and general anesthesia","volume":"23","author":"Heurteaux","year":"2004","journal-title":"EMBO J"},{"issue":"6","key":"10.1016\/j.molpha.2026.100155_bib31","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/sj.bjp.0706068","article-title":"Inhibition of the human two-pore domain potassium channel, TREK-1, by fluoxetine and its metabolite norfluoxetine","volume":"144","author":"Kennard","year":"2005","journal-title":"Br J Pharmacol"},{"issue":"5-6","key":"10.1016\/j.molpha.2026.100155_bib32","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.neuropharm.2011.06.020","article-title":"TREK-1 isoforms generated by alternative translation initiation display different susceptibility to the antidepressant fluoxetine","volume":"61","author":"Eckert","year":"2011","journal-title":"Neuropharmacology"},{"issue":"6","key":"10.1016\/j.molpha.2026.100155_bib33","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/cns.12384","article-title":"The role of the two-pore domain potassium channel TREK-1 in the therapeutic effects of escitalopram in a rat model of poststroke depression","volume":"21","author":"Lin","year":"2015","journal-title":"CNS Neurosci Ther"},{"issue":"5","key":"10.1016\/j.molpha.2026.100155_bib34","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/8084","article-title":"Inhalational anesthetics activate two-pore-domain background K+ channels","volume":"2","author":"Patel","year":"1999","journal-title":"Nat Neurosci"},{"issue":"1","key":"10.1016\/j.molpha.2026.100155_bib35","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.bbrc.2006.12.199","article-title":"Antipsychotics inhibit TREK but not TRAAK channels","volume":"354","author":"Thummler","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"10.1016\/j.molpha.2026.100155_bib36","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1124\/jpet.107.125245","article-title":"Potent inhibition of native TREK-1 K+ channels by selected dihydropyridine Ca2+ channel antagonists","volume":"323","author":"Liu","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.molpha.2026.100155_bib37","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/s41467-025-67819-w","article-title":"Light-induced analgesia provides a drug-free optical method for pain relief via activation of TRAAK k+ channels","volume":"17","author":"Bied","year":"2026","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.molpha.2026.100155_bib38","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1111\/bph.13019","article-title":"Differential sensitivity of TREK-1, TREK-2 and TRAAK background potassium channels to the polycationic dye ruthenium red","volume":"172","author":"Braun","year":"2015","journal-title":"Br J Pharmacol"},{"issue":"5","key":"10.1016\/j.molpha.2026.100155_bib39","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.chembiol.2020.01.011","article-title":"Polynuclear ruthenium amines inhibit K2P channels via a \"finger in the dam\" mechanism","volume":"27","author":"Pope","year":"2020","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.molpha.2026.100155_bib40","article-title":"Cannabinoid inhibition of mechanosensitive K+ channels","author":"Docter","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.molpha.2026.100155_bib41","article-title":"Block of TREK and TRESK K2P channels by lamotrigine and two derivatives sipatrigine and CEN-092","volume":"26","author":"Walsh","year":"2021","journal-title":"Biochem Biophys Rep"},{"issue":"7","key":"10.1016\/j.molpha.2026.100155_bib42","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1038\/s44318-026-00710-6","article-title":"Structural determinants for GPCR-mediated inhibition of TASK K2P channels by diacylglycerol and its dysfunction in disease","volume":"45","author":"Jouen-Tachoire","year":"2026","journal-title":"EMBO J"},{"issue":"3","key":"10.1016\/j.molpha.2026.100155_bib43","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1124\/jpet.123.001659","article-title":"Rapid Characterization of the functional and pharmacological consequences of Cant\u00fa syndrome KATP channel mutations in intact cells","volume":"386","author":"Gao","year":"2023","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.molpha.2026.100155_bib44","article-title":"An improved platform for functional assessment of large protein libraries in mammalian cells","volume":"48","author":"Matreyek","year":"2020","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"10.1016\/j.molpha.2026.100155_bib45","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J Comput Chem"},{"issue":"16","key":"10.1016\/j.molpha.2026.100155_bib46","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J Comput Chem"},{"issue":"6429","key":"10.1016\/j.molpha.2026.100155_bib47","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1126\/science.aav0569","article-title":"A pharmacological master key mechanism that unlocks the selectivity filter gate in K+ channels","volume":"363","author":"Schewe","year":"2019","journal-title":"Science"},{"issue":"32","key":"10.1016\/j.molpha.2026.100155_bib48","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.1021\/bi500525s","article-title":"Structures of KcsA in complex with symmetrical quaternary ammonium compounds reveal a hydrophobic binding site","volume":"53","author":"Lenaeus","year":"2014","journal-title":"Biochemistry"},{"issue":"1","key":"10.1016\/j.molpha.2026.100155_bib49","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1113\/jphysiol.2004.081059","article-title":"Thermosensitivity of the two-pore domain K+ channels TREK-2 and TRAAK","volume":"564","author":"Kang","year":"2005","journal-title":"J Physiol"},{"issue":"11","key":"10.1016\/j.molpha.2026.100155_bib50","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1093\/emboj\/19.11.2483","article-title":"TREK-1 is a heat-activated background K(+) channel","volume":"19","author":"Maingret","year":"2000","journal-title":"EMBO J"},{"issue":"8","key":"10.1016\/j.molpha.2026.100155_bib51","doi-asserted-by":"crossref","DOI":"10.1085\/jgp.202012812","article-title":"Norfluoxetine inhibits TREK-2 K2P channels by multiple mechanisms including state-independent effects on the selectivity filter gate","volume":"153","author":"Proks","year":"2021","journal-title":"J Gen Physiol"},{"issue":"6","key":"10.1016\/j.molpha.2026.100155_bib52","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.neuron.2008.04.016","article-title":"Alternative translation initiation in rat brain yields K2P2.1 potassium channels permeable to sodium","volume":"58","author":"Thomas","year":"2008","journal-title":"Neuron"},{"issue":"23","key":"10.1016\/j.molpha.2026.100155_bib53","doi-asserted-by":"crossref","first-page":"5651","DOI":"10.1113\/jphysiol.2008.161927","article-title":"Control of the single channel conductance of K2P10.1 (TREK-2) by the amino-terminus: role of alternative translation initiation","volume":"586","author":"Simkin","year":"2008","journal-title":"J Physiol"},{"issue":"23","key":"10.1016\/j.molpha.2026.100155_bib54","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.1111\/bph.12596","article-title":"Modulation of K2P 2.1 and K2P 10.1 K(+) channel sensitivity to carvedilol by alternative mRNA translation initiation","volume":"171","author":"Kisselbach","year":"2014","journal-title":"Br J Pharmacol"},{"issue":"5","key":"10.1016\/j.molpha.2026.100155_bib55","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1124\/mol.113.091199","article-title":"Influence of the N terminus on the biophysical properties and pharmacology of TREK1 potassium channels","volume":"85","author":"Veale","year":"2014","journal-title":"Mol Pharmacol"},{"issue":"9","key":"10.1016\/j.molpha.2026.100155_bib56","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/nn1749","article-title":"Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype","volume":"9","author":"Heurteaux","year":"2006","journal-title":"Nat Neurosci"},{"issue":"24","key":"10.1016\/j.molpha.2026.100155_bib57","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1161\/CIRCULATIONAHA.124.070284","article-title":"Circulating autoantibodies targeting TREK-1 in patients with short-coupled ventricular fibrillation","volume":"150","author":"Li","year":"2024","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.molpha.2026.100155_bib58","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2023.38.e173","article-title":"Population pharmacokinetic-pharmacodynamic modeling of carvedilol to evaluate the effect of cytochrome P450 2D6 genotype on the heart rate reduction","volume":"38","author":"Hwang","year":"2023","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.molpha.2026.100155_bib59","first-page":"2911","article-title":"Dose proportionality and pharmacokinetics of carvedilol sustained-release formulation: a single dose-ascending 10-sequence incomplete block study","volume":"9","author":"Kim","year":"2015","journal-title":"Drug Des Devel Ther"},{"issue":"8","key":"10.1016\/j.molpha.2026.100155_bib60","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1002\/jps.23626","article-title":"Population pharmacokinetics of carvedilol in patients with congestive heart failure","volume":"102","author":"Nikolic","year":"2013","journal-title":"J Pharm Sci"},{"issue":"11","key":"10.1016\/j.molpha.2026.100155_bib61","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.1021\/acs.jmedchem.5b00671","article-title":"Perspectives on the two-pore domain potassium channel TREK-1 (TWIK-related K(+) channel 1). A novel therapeutic target?","volume":"59","author":"Vivier","year":"2016","journal-title":"J Med Chem"},{"issue":"3","key":"10.1016\/j.molpha.2026.100155_bib62","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0893-133X(95)00070-T","article-title":"Distribution of fluphenazine and its metabolites in brain regions and other tissues of the rat","volume":"13","author":"Aravagiri","year":"1995","journal-title":"Neuropsychopharmacology"}],"container-title":["Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X26000556?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X26000556?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T03:50:05Z","timestamp":1790049005000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026895X26000556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":62,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0026895X26000556"],"URL":"https:\/\/doi.org\/10.1016\/j.molpha.2026.100155","relation":{},"ISSN":["0026-895X"],"issn-type":[{"value":"0026-895X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A conserved conformation-dependent mechanism for the TREK two-pore domain potassium channel inhibitors carvedilol and fluphenazine","name":"articletitle","label":"Article Title"},{"value":"Molecular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molpha.2026.100155","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100155"}}